The closing price of Aridis Pharmaceuticals Inc. (NASDAQ: ARDS) was $1.17 for the day, down -0.85% from the previous closing price of $1.18. In other words, the price has decreased by -$0.0100 from its previous closing price. On the day, 2764320 shares were traded. ARDS stock price reached its highest trading level at $1.4500 during the session, while it also had its lowest trading level at $1.1500.
Our analysis of ARDS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.20 and its Current Ratio is at 0.20.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, ROTH Capital on February 19, 2020, initiated with a Buy rating and assigned the stock a target price of $18.
For the stock, the TTM Price-to-Sale (P/S) ratio is 9.09.
Stock Price History:
Over the past 52 weeks, ARDS has reached a high of $2.94, while it has fallen to a 52-week low of $0.68. The 50-Day Moving Average of the stock is 1.0430, while the 200-Day Moving Average is calculated to be 1.2571.
ARDS traded an average of 122.89K shares per day over the past three months and 210.72k shares per day over the past ten days. A total of 17.70M shares are outstanding, with a floating share count of 17.60M. Insiders hold about 40.26% of the company’s shares, while institutions hold 10.20% stake in the company. Shares short for ARDS as of Oct 13, 2022 were 208.99k with a Short Ratio of 0.10M, compared to 125.74k on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 1.18% and a Short% of Float of 1.29%.
The firm’s stock currently is rated by 3 analysts. On average, analysts expect EPS of -$0.17 for the current quarter, with a high estimate of $0.45 and a low estimate of -$0.49, while EPS last year was -$1.94. The consensus estimate for the next quarter is $0.13, with high estimates of $1.41 and low estimates of -$0.51.
Analysts are recommending an EPS of between $1.42 and -$1.88 for the fiscal current year, implying an average EPS of -$0.78. EPS for the following year is -$0.88, with 3 analysts recommending between $0.3 and -$1.59.
A total of 3 analysts have provided revenue estimates for ARDS’s current fiscal year. The highest revenue estimate was $85M, while the lowest revenue estimate was $1.48M, resulting in an average revenue estimate of $29.53M. In the same quarter a year ago, actual revenue was $1.53M, up 1,823.80% from the average estimate.